AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04729114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dose
Study NCT04729114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Oral capsule
Study NCT05243108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary nucleotides
Description: 1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
Study NCT05243108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04928001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: internet based iCBT program, Youth Thrive
Description: iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
Study NCT05254678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general exercise
Description: A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
Study NCT05254678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general exercise
Description: A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Alemtuzumab
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Fingolimod
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Glatiramer acetate
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon beta
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ocrelizumab
Description: Administered as specified in the treatment arm.
Study NCT05036018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve Evolut Pro and Pro+
Description: The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
Study NCT05036018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
Study NCT06263491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by PO
Study NCT06263491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO
Study NCT06349590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fiber/low-fat meals
Description: Meals with Low fat/High fiber
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ofatumumab
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon beta-1a
Description: Administered as specified in the treatment arm.
Study NCT05376982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment
Description: Using Neurodevelopmental Treatment Method
Study NCT05159219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Anti-inflammatory
Study NCT05159219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert ingredients
Study NCT06364423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HuCD19 ( Anti-CD19)CAR T cells
Description: 1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
Study NCT06364423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Study NCT05376982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training along with conventional therapy
Description: Using Body weight supported treadmill training along with conventional therapy Method
Study NCT03631771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide
Description: Iopromide administered intravascularly
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Ponesimod
Description: Administered as specified in the treatment arm.
Study NCT05688436 — intervention group
Intervention type: DRUG
Intervention: Siponimod
Description: Administered as specified in the treatment arm.
Study NCT03631771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioversol
Description: Ioversol administered intravascularly
Study NCT06098677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carotenoids supplementation
Description: Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
Study NCT06098677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral supplementation of a soft gel capsule containing only placebo oil
Study NCT04627090 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
Study NCT06364423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
Study NCT06457971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ventral Hernia Repair
Description: The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
Study NCT06514677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Carbon Tip
Description: Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
Study NCT06514677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Curette
Description: Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
Study NCT05766319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Description: Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)
Study NCT05766319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings BPM Connect
Description: Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)
Study NCT05766319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Body
Description: Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)
Study NCT04751799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset before colposcopy
Description: Patients wear a virtual headset presenting 360° 3D views of relaxing environments
Study NCT05103553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Clinic
Description: Follow-up in outpatient clinic
Study NCT05313269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISAFE technique for adductor canal catheter insertion
Description: Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
Study NCT05313269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique for adductor canal catheter insertion
Description: Adductor canal block catheter tip located lateral to the femoral artery.
Study NCT04934839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.
Description: Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts.
Study NCT06464705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF treatment
Description: Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
Study NCT06464705 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
Study NCT04938310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy
Study NCT04938310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy
Study NCT04938310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: support garment
Description: A custom made support garment
Study NCT05243745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% PVM/MA + 5% KNO3 Combination
Description: Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
Study NCT05243745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3% PVM/MA only
Description: Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
Study NCT05243745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 Only
Description: Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
Study NCT05243745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular Fluoride
Description: Toothpaste containing regular fluoride will be used as negative control.
Study NCT06302348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepiapterin
Description: Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
Study NCT04771416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBKR03
Description: Single dose of PBKR03, via intra cisterna magna
Study NCT06364423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
Study NCT04751799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset during colposcopy
Description: Patients wear a virtual headset presenting 360° 3D views of distracting environments
Study NCT06471920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Patients randomized to the educational control group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
Study NCT06566534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Flu shot messages via SMS
Study NCT06167317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally
Study NCT05955820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspension system
Description: Participants will be tested by four exercises designed for impingement syndrome using the suspension system
Study NCT05955820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dumbbells
Description: Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
Study NCT06471920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
Study NCT06260670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter
Description: Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL).
Study NCT05416827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: slow-release dexamethasone implant
Description: Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
Study NCT05416827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow-release dexamethasone implant
Description: Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
Study NCT06018311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising together
Description: The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
Study NCT06501066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Patients assigned to UC-MSC administration groups will receive one administrations
Study NCT06501066 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: umbilical cord mesenchymal stem cells
Description: Patients assigned to UC-MSC administration groups will receive one administrations
Study NCT06328504 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cashew immunotherapy
Description: Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
Study NCT06478030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)
Description: The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
Study NCT06167317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Administered intravenously
Study NCT06567704 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Interviews
Study NCT06368700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalex Knee Cartilage System
Description: Surgical implantation of the Hyalex Knee Cartilage System
Study NCT04819841 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nula-cel Drug Product
Description: nula-cel is administered via IV infusion following a myeloablative conditioning regimen
Study NCT04621357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI will include differents sequences.
Study NCT04621357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological biomarkers
Description: Biological biomarkers will include a set of systemic inflammatory markers
Study NCT06242431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group serratus posterior superior intercostal plane block (SPSIPB)
Description: SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
Study NCT06242431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group pectoralis nerve block (PECS-II)
Description: PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
Study NCT05470491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.
Study NCT05470491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
Study NCT05470491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo HCT
Description: bone marrow transplant
Study NCT05470491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
Study NCT05470491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
Study NCT06480981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noribogaine
Description: Noribogaine capsules